No Eclipse in Sight for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) as it Moves toward Clinical Trials
Proprietary biosynthesis process to produce cannabinoids Cannabinoid bioinformatics system that identifies optimal R&D pathways Lead candidate targeting billion dollar market…